血清microRNA-25对脓毒症患者病情严重程度及预后的评估价值

王静波; 燕宪亮; 王厚清; 许铁

doi:10.13201/j.issn.1009-5918.2020.06.015

血清microRNA-25对脓毒症患者病情严重程度及预后的评估价值

- 徐州医科大学附属医院急救中心(江苏徐州, 221002)

详细信息

通讯作者: 燕宪亮,E-mail:docyxl@163.com

中图分类号: R631.2

收稿日期: 2020-03-19

Evaluation value of serum microRNA-25 on severity and prognosis of sepsis patients

- Emergency Center of the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China

More Information

Corresponding author: YAN Xianliang, E-mail: docyxl@163.com

Received Date: 19 March 2020

摘要

摘要: 目的:探究血清microRNA-25对评估脓毒症患者病情严重程度及预后的价值,分析影响脓毒症患者预后的危险因素。方法:选取82例脓毒症患者作为研究对象,根据患者病情严重程度分为脓毒症组及脓毒性休克组,30例健康体检者作为对照组。采用实时荧光定量检测方法(RT-PCR)检测血清microRNA-25表达量。记录入组患者的一般资料(性别、年龄、感染部位)和相关指标(WBC、CRP、PCT、D-D、Lac、Cys-C、SOFA评分、APACHEⅡ评分)。根据28 d预后情况分为存活组和死亡组。筛选影响脓毒症患者预后的独立危险因素,评估死亡独立危险因素对脓毒症患者死亡的预测效果。结果:①脓毒症组和脓毒性休克组间、存活组和死亡组间的性别、年龄、感染部位等差异均无统计学意义(P>0.05)。②与脓毒症组相比,脓毒性休克组患者的PCT、D-D、Lac、Cys-C、SOFA评分及APACHEⅡ评分均升高(P<0.05);③脓毒性休克组患者血清microRNA-25表达量低于脓毒症组(P<0.05);④与存活组相比,死亡组患者的PCT、D-D、Lac、Cys-C、SOFA评分及APACHEⅡ评分显著升高(P<0.05);死亡组患者microRNA-25明显低于存活组,差异有统计学意义(P<0.05)。⑤PCT、D-D、Lac、Cys-C、microRNA-25、SOFA评分、APACHEⅡ评分是脓毒症患者28 d死亡危险因素,且Lac、Cys-C、microRNA-25、SOFA评分是脓毒症患者28 d死亡的独立危险因素。结论:血清microRNA-25可作为评估脓毒症患者病情严重程度及判断预后的生物标志物;Lac、Cys-C、microRNA-25、SOFA评分是脓毒症患者28 d死亡的独立危险因素。
- 脓毒症 /
- 脓毒性休克 /
- microRNA-25
Abstract: Objective: To explore the value of serum microRNA-25 in evaluating the severity and prognosis of sepsis patients, and analyze the risk factors affecting the prognosis of sepsis patients. Method: Eighty-two patients with sepsis were selected as the research object, and the patients were divided into sepsis group and septic shock group according to the severity of the disease. Thirty healthy subjects were used as the control group. Real-time fluorescence quantitative detection method(RT-PCR) was used to detect the expression of microRNA-25 in serum. Record the general information(sex, age, infection site) and related indicators(WBC, CRP, PCT, D-D, Lac, Cys-C, SOFA score, APACHE Ⅱ score) of the enrolled patients. According to the prognosis of 28 days, they were divided into survival group and death group. The independent risk factors that can affect the prognosis of sepsis patients were screened, and the predictive effect of independent risk factors for death of sepsis patients was assessed. Result: ①The differences in age, gender and infection site were not statistically significant between sepsis group and septic shock group, as well as survival group and death group. ②Compared with sepsis group, PCT, D-D, Lac, Cys-C, SOFA and APACHE Ⅱ scores in septic shock group were all increased(P<0.05). ③The expression of serum microRNA-25 in septic shock group was lower than that in sepsis group(P<0.05). ④Compared with the survival group, PCT, D-D, Lac, Cys-C, SOFA and APACHE Ⅱ scores of the patients in the death group were significantly higher(P<0.05); microRNA-25 in the dead group was significantly lower than that in the surviving group(P<0.05). ⑤PCT, D-D, Lac, Cys-C, microRNA-25, SOFA scores and APACHE Ⅱ scores are risk factors for 28-day death of sepsis patients, and Lac, Cys-C, microRNA-25 and SOFA scores are independent risk factors for 28-day death of sepsis patients.Conclusion: Serum microRNA-25 can be used as a biomarker to evaluate the severity and prognosis of sepsis patients. Lac, Cys-C, microRNA-25 and SOFA scores are independent risk factors for 28-day death in sepsis patients.
- sepsis /
- septic shock /
- microRNA-25

HTML全文

参考文献(18)

[1]	Singer M,Deutschman CS,Seymour CW,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
[2]	薄禄龙,卞金俊,邓小明,等.2016年脓毒症最新定义与诊断标准:回归本质重新出发[J].中华麻醉学杂志,2016,36(3):259-262.
[3]	Rhodes A,Evans E,A1 hazzani W,et al.Surviving sepsis campaign:international guidellnes for management of sepsis and septic shock:2016[J].Intensive cflre Med,2017,43(3):304-377.
[4]	侯果.miRNA作为脓毒症及其并发症生物标志物的研究进展[J].微循环学,2018,28(4):81-85.
[5]	刘卜玮,蔡明成,杨雪,等.microRNA调控细胞凋亡的研究进展[J].生理科学进展,2018,49(4):309-314.
[6]	Momen-heravi F,Bala S.miRNA regulation of innate immunity[J].Leukoc Biol,2018,103(6):1205-1217.
[7]	韩乐,陈文娟,雷光焰,等.microRNA-21、microRNA-25在肺癌组织中的表达及意义[J].陕西医学杂志,2019,48(12):1596-1600.
[8]	乔芳,郭璞,刘相莲,等.microRNA与炎症因子之间调控的研究进展[J],生理科学进展,2018,49(2):120-124.
[9]	Ardekani AM,Naeini MM.The role of microRNAS in human diseases[J].Scand J Immunol,2010,71(4):227-231.
[10]	Wu DD,Li T,Ji XY.Dendritic cells in sepsis:pathological alterations and therapeutic implications[J].J Immunol Res,2017,2017:3591248.
[11]	赵鹏跃,杜晓辉.脓毒症免疫联合治疗研究进展[J].解放军医学杂志,2019,44(5):434-439.
[12]	姚咏明,张艳敏.脓毒症发病机制最新认识[J].医学研究生学报,2017,30(7):678-683.
[13]	Yao YL,Sun FY,Lei M.MiRNA-25 inhibits sepsis-induced cardiomyocyte apoptosis by targeting PTEN[J].Biosci Rep,2018,38(2):BSR20171511.
[14]	Zhu CY,Che T,Liu B.Inhibitory effects of miR-25 targeting HMGB1 on macrophage secretion of inflammatory cytokines in sepsis[J].Oncology Letters,2018,16:5027-5033.
[15]	Caserta S,Kern F,Cohen J,et al.Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome(SIRS)[J].Sci Rep,2016,6:28006.
[16]	Benz F,Roy S,Trautwein C,et al.Circulating microRNAs as biomarkers for sepsis[J].Int J Mol Sci,2016,17(1):78.
[17]	Yao L,Liu Z,Zhu J,et al.Clinical evaluation of circulating microRNA-25 level change in sepsis and its potential relationship with oxidative stress[J].Int J Clin Exp Pathol,2015,8(7):7675-7684.
[18]	刘启方,黄晶,田龙海,等.microRNA-25通过HMGB1途径降低缺氧/复氧H9C2心肌细胞纤维化[J].基础免疫学,2019,12(35):1416-1420.